Healx
Healx is one of the few AI - based discovery companies that have successfully shown the power of their approach across multiple indications from neuroscience to oncology. Their lead program for neurofibromatosis type 1 (NF1) is already in Ph2, within only 4 years of starting the discovery program. SCI Ventures and Healx have partnered to create a neuro-regeneration program with a focus on chronic SCI.
How they’re delivering breakthroughs
Healx' AI platform analyses millions of drug and disease data points from multiomic data to find novel connections that could be turned into new treatment opportunities. Their technology offers the opportunity to uncover new, most promising therapeutic targets and match them with repurposable drugs. This ensures novelty of a therapeutic approach whilst benefitting from an accelerated regulatory and R&D pathway.
How they’re making a difference
As part of our investment, SCI Ventures has partnered with Healx to create a neuro-regeneration program with chronic SCI as focus indication. This opens the gate to an accelerated development of novel therapeutic strategies for 20M people globally without any treatment options and lays the foundation to an expansion into adjacent indication areas with similar biology.
